What Augmentin Retard Treats: Main Uses and Benefits

Augmentin Retard is commonly used to help with conditions characterized by periods of heightened symptoms resulting from bacterial infections that may be difficult to manage. Its application is relevant for addressing the infectious cause and easing the associated systemic and localized discomfort.

This extended-release medication is relevant for use in certain severe bacterial infections, such as community-acquired pneumonia and acute bacterial sinusitis.

Therapeutic Scope and Patient Support

This medication is applied in contexts marked by increased discomfort or tension related to bacterial infection. It is commonly used to help with serious bacterial infections affecting the lungs and airways and potentially severe skin and soft tissue infections. It is relevant for managing symptoms that interfere with daily comfort, such as localized distress or difficulty breathing, and provides support that helps maintain a sense of stability when symptoms are more noticeable.

The core benefit is providing support that helps ease the overall symptom burden associated with acute systemic imbalance, such as fever, generalized discomfort, and fatigue. By being used for managing the infectious cause, it offers symptomatic relief that helps patients cope more steadily with difficult acute episodes and supports general well-being during symptomatic phases.

“This medication is considered relevant for use in clinical settings that involve acute or unstable symptom patterns related to specific severe bacterial infections.”

Quick Fact: Relief for Systemic Discomfort This medicine is applied in scenarios where symptoms create noticeable physiological strain, helping to ease the overall symptom load and support general comfort during periods of acute infection.

Who Can and Cannot Use Augmentin Retard

The eligibility for using the modified-release formulation of Amoxicillin and Clavulanate (Augmentin Retard) is strictly defined by regulatory documents, focusing on patient history, organ function, and age.

Absolute Contraindications

The medicine must not be used by patients with a documented history of a serious hypersensitivity reaction to amoxicillin, clavulanate, or any other beta-lactam antibacterial drug (e.g., penicillins or cephalosporins). It is also contraindicated for individuals with a history of cholestatic jaundice or hepatic dysfunction associated with prior amoxicillin/clavulanate treatment.

Organ Function and Condition Restrictions

Augmentin Retard is contraindicated for patients with severe renal impairment (creatinine clearance < 30 mL/min) or those undergoing hemodialysis. Use in patients with hepatic impairment is permitted but requires caution and regular monitoring of liver function. Use should be avoided in patients with Infectious Mononucleosis.

Age and Special Population Rules

The extended-release tablet is primarily intended for adults. Its use is not recommended in pediatric patients weighing less than mathbf40 kg, as efficacy and safety have not been established for this group. During pregnancy, the medicine should only be used when clearly needed, and conditional restrictions apply regarding its use in women with PPROM. For nursing mothers, use is generally acceptable, but the infant must be monitored for potential adverse effects.

Interactions with other medicines and products

This section describes documented interaction patterns for Augmentin Retard based on regulatory sources, focusing on how co-administered substances or conditions affect drug exposure and function.

Drug-Drug and Pharmacodynamic Interactions

Co-administration with Probenecid is not recommended due to a pharmacokinetic interaction where it inhibits the renal clearance of Amoxicillin, leading to prolonged and elevated plasma concentrations of the antibiotic component. When combined with oral anticoagulants, an effect on blood coagulation may occur, potentially increasing the prolongation of prothrombin time, which necessitates appropriate monitoring. Concurrent use with Allopurinol is associated with an increased incidence of rash. Furthermore, this medicine may reduce the efficacy of oral contraceptives.

Food, Timing, and Diagnostic Constraints

The extended-release tablet must be administered at the start of a standardized meal to optimize the absorption of its active ingredients. Conversely, consumption with a high-fat meal is not recommended, as this is documented to decrease the absorption of the Clavulanate component. Regarding laboratory procedures, the medicine may cause false positive results in non-enzymatic urine glucose tests and the Direct Antiglobulin Test (Coombs test). Due to critical clearance requirements, the modified-release formulation is also contraindicated in patients with severe renal impairment or those on hemodialysis.

Augmentin Retard, a combination product, functions through the dual mechanistic actions of its two components: amoxicillin and clavulanic acid.

Amoxicillin is a beta-lactam derivative that acts as an irreversible inhibitor. It targets and binds covalently to penicillin-binding proteins (PBPs), which are bacterial transpeptidases essential for the final cross-linking stage of peptidoglycan synthesis. This inhibition prevents the formation of a structurally sound bacterial cell wall. The subsequent loss of cell wall integrity leads to osmotic instability and consequential cell lysis.

Clavulanic acid is a beta-lactamase inhibitor with minimal inherent activity on its own. Its mechanism involves acting as a suicide inhibitor by binding irreversibly to the active site of beta-lactamase enzymes produced by certain bacteria. beta-lactamase enzymes normally hydrolyze the beta-lactam ring of amoxicillin, rendering it pharmacologically inactive. By deactivating these enzymes, clavulanic acid ensures the preservation of amoxicillin's molecular structure, permitting its subsequent binding to PBPs and continuation of the cell wall synthesis inhibition cascade.

How to Use Augmentin Retard

Augmentin Retard (amoxicillin and clavulanate potassium extended-release tablets) is a medicine for oral use only.

Administration Requirements

Dosing and Schedule

Standard dosing for adults and children weighing 40 kg or more is typically a fixed schedule, such as one tablet taken three times a day, though the dose and frequency can vary based on the specific strength of the formulation prescribed.

• Dosing Frequency: The medicine must be taken at the prescribed fixed time intervals to maintain appropriate levels in the body.
• Course Duration: Treatment should not be extended beyond 14 days without clinical review.
• Missed Dose: If a dose is missed, it should be taken as soon as the patient remembers, unless it is almost time for the next scheduled dose; the patient should not double the next dose.

Population-Specific Rules

Dose adjustments are required for patients with renal impairment (decreased kidney function). For example, a patient with a creatinine clearance below 30 ml/ min will need a modified dosage regimen. No dose adjustment is generally necessary for elderly patients.

Research Evidence: Overview of Studies for Augmentin Retard

Evidence for Use in Acute Bacterial Sinusitis

The research evaluating the extended-release formulation for acute bacterial sinusitis (ABS) primarily involved randomized, double-blind trials where the product was studied against other approved formulations. These studies were applied in research contexts involving fluctuating or unstable symptoms typical of ABS in adult patients. Researchers monitored two primary types of measures: clinical outcome measures, which involved tracking how symptoms evolved in the observed populations, and bacteriological outcome measures, which focused on tracking the status of the causative pathogen.

However, existing evidence offers limited insight into the long-term patterns of symptom recurrence or the stability of the outcomes related to physical discomfort past the initial follow-up visit. Additionally, the research so far indicates that studies have focused mainly on adults, meaning data for certain groups, such as pediatric patients weighing less than 40 kg or adults with severe kidney conditions, remain insufficient.

Evidence for Use in Community-Acquired Pneumonia

Research exploring the extended-release formulation in community-acquired pneumonia (CAP) largely consists of large-scale Randomized Controlled Trials (RCTs). These studies were conducted during periods of increased symptom activity, focusing on adult patients, some of whom were stratified by mortality risk. Research examined outcomes related to systemic or functional imbalance, specifically tracking measures of clinical status and bacteriological status at defined time intervals.

Findings indicate that some studies reported patterns meeting the non-inferiority criteria when the product was studied alongside active treatment comparators, while others described variability in meeting those same research goals. A key research limitation is that the primary trial structure was designed to explore if the product was "not worse" than existing treatments, leaving the question of clear superior effect unaddressed in the main study results. Furthermore, the results apply only to the populations studied.

Evidence in Special Populations and Uncertainties

The research base primarily consists of studies involving healthy, non-pregnant adults. Specific dedicated studies for the extended-release formulation are unavailable for several important groups. Data for certain groups remain insufficient, particularly for pediatric patients who weigh less than 40 kg.

Research has also excluded individuals with severe renal impairment (significant kidney issues), and the evidence is lacking for how patterns observed in the studies would apply to individuals with this specific comorbidity. This highlights areas where more research is needed, such as the impact on highly resistant bacteria or the lack of studies designed to demonstrate superiority over existing treatments.

Key Studies & References

1. World Health Organization (WHO) Model List of Essential Medicines (Amoxicillin + Clavulanic Acid)
2. MedlinePlus Drug Information: Amoxicillin and Clavulanate

Common questions about Augmentin Retard (FAQ)

Q: What is the proper dosage of Augmentin Retard for an adult?

Official administration guidelines indicate that standard dosing for adults is typically a fixed schedule, often involving one tablet taken three times a day. However, the exact dose and frequency can vary based on the specific strength of the formulation. A healthcare professional prescribes the precise schedule based on the patient's condition.

Q: Can I take Augmentin Retard if I am pregnant?

According to official regulatory sources, Augmentin Retard should only be used during pregnancy when it is clearly needed. Use in pregnant women with certain conditions may be subject to specific conditional restrictions. The decision to use this medication during pregnancy is made in consultation with a healthcare provider.

Q: What is the difference between this 'Retard' version and a regular Augmentin tablet?

The 'Retard' designation means this is a modified-release tablet (or sustained-release formulation). This specialized design releases the active ingredients, Amoxicillin and Clavulanic Acid, slowly and consistently after swallowing. This differs from a regular, immediate-release tablet, allowing the modified-release formulation to deliver ingredients over a longer duration.

Q: Does this antibiotic make my birth control pill less effective?

Regulatory documents indicate that this medicine may reduce the efficacy of oral contraceptives (birth control pills) due to a known interaction. Because the medicine can affect how well oral contraceptives may work, the official labeling suggests monitoring. Individuals concerned about this interaction often consult their healthcare provider to discuss whether alternative or additional contraceptive methods are needed.

Q: What should I avoid drinking (like alcohol or juice) when I take this medicine?

Official product information, such as the Summary of Product Characteristics (SmPC), does not typically list a specific contraindication or warning against the use of alcohol while taking this medicine. Similarly, the regulatory labeling does not provide specific dietary restrictions regarding common fruit juices or other beverages.

Storage and Disposal Requirements for Augmentin Retard

Official regulatory labeling outlines specific requirements to maintain the stability and integrity of Augmentin Retard (amoxicillin/clavulanate extended-release) tablets.

Storage Conditions

The medicine must be stored at room temperature, specifically below 25°C (77°F), and must be protected from both light and moisture. It is required that the product be kept out of the sight and reach of children to prevent accidental ingestion. The tablets must remain in the original container and must not be frozen.

Disposal Instructions

Unused or expired Augmentin Retard must not be disposed of via wastewater (such as flushing) or placed into household waste. For proper pharmaceutical waste handling, individuals must ask a pharmacist how to correctly discard any medicine that is no longer needed.